Medscape InDiscussion: Endometrial Cancer copertina

Medscape InDiscussion: Endometrial Cancer

Medscape InDiscussion: Endometrial Cancer

Di: Medscape
Ascolta gratuitamente

A proposito di questo titolo

 Listen to Medscape InDiscussion: Endometrial Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s1-ep1-2026a10007qe. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.Copyright 2026, Medscape Disturbo fisico e malattia Igiene e vita sana Scienza
Episodi
  • Route 66 SPORE and the Direction of Endometrial Cancer Research

    Route 66 SPORE and the Direction of Endometrial Cancer Research
    Apr 1 2026

    Drs Ursula A. Matulonis and David G. Mutch discuss past and present endometrial cancer research, including the Route 66 SPORE.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep2-2026a10006ic. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    Route 66 Endometrial Cancer SPORE https://dctd.cancer.gov/research/spores/state/wustl-endometrial

    Final Analysis of RTOG 9708: Adjuvant Postoperative Irradiation Combined With Cisplatin/Paclitaxel Chemotherapy Following Surgery for Patients With High-Risk Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/16545437/

    Pelvic Radiation With Concurrent Chemotherapy Compared With Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer https://pubmed.ncbi.nlm.nih.gov/10202164/

    Surgical-Pathological Findings in Type 1 and 2 Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study on GOG-210 Protocol https://pubmed.ncbi.nlm.nih.gov/28392124/

    GOG Foundation https://www.gog.org/

    The Latest Updates in Translational Science at NRG Oncology (October 2025) https://www.nrgoncology.org/Home/News/Post/the-latest-updates-in-translational-science-at-nrg-oncology-october-2025/

    Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/

    Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post-Hoc Analysis by Molecular Classification From a Randomised Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/40921169/

    FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

    Practical Guidance for Assessing and Reporting Lymphovascular Space Invasion (LVSI) in Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/38937066/

    Surgical Pathologic Spread Patterns of Endometrial Cancer. A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/3652025/

    Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/

    AXL Inhibition Improves the Therapeutic Efficacy of Trastuzumab in High-Risk Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/41270342/

    Patient-Derived Xenograft Mouse Models: A High Fidelity Tool for Individualized Medicine https://pubmed.ncbi.nlm.nih.gov/30655732/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    23 min
  • The Future of Endometrial Cancer Therapeutics: Phase 3 Trials of ADCs and Beyond

    The Future of Endometrial Cancer Therapeutics: Phase 3 Trials of ADCs and Beyond
    Apr 1 2026
    Drs Ursula Matulonis and Brian Slomovitz discuss phase 3 trials of ADCs in endometrial cancer and what's to come in the field of endometrial cancer therapeutics. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep1-2026a10006ib. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review https://pubmed.ncbi.nlm.nih.gov/40212845/ Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/ Standardized Pathology Report for HER2 Testing in Compliance With 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37770765/ Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) https://clinicaltrials.gov/study/NCT07044336 Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination With Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/36736157/ First in Human Study of IMGN151 in Recurrent Gynaecological Cancers https://clinicaltrials.gov/study/NCT05527184 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01) https://clinicaltrials.gov/study/NCT06989112 Pembrolizumab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: Overall Survival and Exploratory Analyses of the NRG GY018 Phase 3 Randomized Trial https://pubmed.ncbi.nlm.nih.gov/40044930/ The GOG Highlight Reel July 2025 https://www.gog.org/wp-content/uploads/2025/08/GOG-Highlight-Reel-July-2025-Presentation-7.26.25.pdf Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection https://pubmed.ncbi.nlm.nih.gov/38892080/ Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) https://pubmed.ncbi.nlm.nih.gov/41385758/ A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/ Mutated p53 Portends Improvement in Outcomes When Bevacizumab Is Combined With Chemotherapy in Advanced/Recurrent Endometrial Cancer: An NRG Oncology Study https://pubmed.ncbi.nlm.nih.gov/33541735/ Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer https://clinicaltrials.gov/study/NCT07198074 WEE1 Inhibitor: Clinical Development https://pubmed.ncbi.nlm.nih.gov/34269904/ Palbociclib Plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial https://pubmed.ncbi.nlm.nih.gov/39657575/ GOG3069: Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-Mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS5639 TP004/#1561 A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study of Nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer https://www.sciencedirect.com/science/article/pii/S1048891X24163530 Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities https://pubmed.ncbi.nlm.nih.gov/41329840/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    25 min
  • Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?

    Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?
    Jun 12 2025

    Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep6-2026a10008nk. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    The Clinical Landscape of Antibody-Drug Conjugates in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39074933/

    FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

    Mechanisms of Resistance to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/36831621/

    TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39745368/

    Single-Cell Analysis Technologies for Cancer Research: From Tumor-Specific Single Cell Discovery to Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/37900181/

    Spatial Transcriptomics for Tumor Heterogeneity Analysis https://pubmed.ncbi.nlm.nih.gov/35899203/

    Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review https://pmc.ncbi.nlm.nih.gov/articles/PMC10516512/

    Current and Emerging Prognostic Biomarkers in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35530346/

    Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

    Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38709212/

    Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    26 min
Ancora nessuna recensione